Such resistance can be overcome by ROCK inhibitors that reduce myosin II activity, leading to DNA damage by generating ROS in immunotherapy-resistant melanoma and decrease in PD-L1 and Treg infiltration [143]. Here, CD274 is linked to melanoma.